From the Editor’s Desk: The emergence of "personalized medicine" in medical care

Patrick Lawler; Wenya Miao; Patrick Williams

doi:10.26443/mjm.v10i1.628

Editorial

Vol. 10 No. 1 (2007)

From the Editor’s Desk: The emergence of "personalized medicine" in medical care

Patrick Lawler
Wenya Miao
Patrick Williams

PDF

DOI: https://doi.org/10.26443/mjm.v10i1.628
Submitted: November 7, 2020
Published: 2020-12-01

Abstract

N/A

References

Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. The Lancet Oncology 2002; 3:83-8.
Yashiro M, et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Research 2001; 61:2676-83.
Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987; 235:177-82.
Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001; 344:783-792
Seshadri, R. et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer Journal of Clinical Oncology 1993; 11: 1936-1942.

Downloads

Download data is not yet available.

Keywords

personalized medicine
personalization
targeted therapies

How to Cite

1.

Lawler P, Miao W, Williams P. From the Editor’s Desk: The emergence of "personalized medicine" in medical care. McGill J Med [Internet]. 2020 Dec. 1 [cited 2024 Nov. 5];10(1). Available from: https://mjm.mcgill.ca/article/view/628

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

[1] Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. The Lancet Oncology 2002; 3:83-8.

[2] Yashiro M, et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Research 2001; 61:2676-83.

[3] Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987; 235:177-82.

[4] Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001; 344:783-792

[5] Seshadri, R. et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer Journal of Clinical Oncology 1993; 11: 1936-1942.